P220020/S008: Lava Liquid Embolic System (Lava LES)
FDA’s recorded scope: implementation of the Automated Viscometer for LAVA LES kinematic viscosity testing
Explore this company’s associated devices, FDA decisions and regulatory history.

MedtechLedger currently links 4 FDA records to the applicant name Sirtex Medical, Inc.. 2 entries are PMA supplements. 2 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Aug 5, 2025 to Jul 9, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code QVG appears in 3 of the 4 linked filings. The collection spans 2 FDA product codes and 2 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P220020, with 3 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.
Applicant mailing address recorded by FDA: 300 Unicorn Park Dr., 2nd Floor ,, Woburn, MA, 01801. Recorded on P220020/S008, decision dated Jul 9, 2026.
Embolization Agent, Vascular; Microspheres Radionuclide.
FDA’s recorded scope: implementation of the Automated Viscometer for LAVA LES kinematic viscosity testing
FDA’s recorded scope: a process change to allow for an additional volume size (SIR-Y003, 0.6 GBq/1 mL) to the existing SIR-Spheres Y-90 resin microspheres product line
FDA’s recorded scope: Approval for a contract manufacturing site located in Wilmington, Massachusetts and to change the legal manufacturer address
FDA’s recorded scope: Approval for extending the shelf-life to three (3) years
Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Lava Liquid Embolic System (Lava LES)P220020/S008 | Sirtex Medical, Inc. | PMA supplement | Jul 9, 2026 | FDA |
SIR-Spheres Y-90 resin microspheresP990065/S019 | Sirtex Medical, Inc. | PMA supplement | May 7, 2026 | FDA |
| Sirtex Medical, Inc. | PMA supplement | Sep 3, 2025 | FDA | |
| Sirtex Medical, Inc. | PMA supplement | Aug 5, 2025 | FDA |
Source updated Nov 9, 2026. Retrieved Nov 21, 2026.